Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Depreciation & Amortization (CF) (2022 - 2026)

Envoy Medical recorded quarterly Depreciation & Amortization (CF) of $73000.0 in Q1 2026, down 8.75% quarter-over-quarter from $80000.0 in Q4 2025, and up 19.67% year-over-year from $61000.0 in Q1 2025.

Envoy Medical's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $73000.0 for Q1 2026.

  • In Q1 2026, Depreciation & Amortization (CF) rose 19.67% year-over-year to $73000.0; the TTM figure through Mar 2026 stood at $329000.0 (up 27.52% YoY), while the FY2025 annual figure was $302000.0, up 74.57% from the prior year.
  • Depreciation & Amortization (CF) came in at $73000.0 for Q1 2026 at Envoy Medical, down from $80000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $100000.0 in Q2 2024 to a low of $15000.0 in Q4 2023.
  • A 5-year average of $53357.1 and a median of $48500.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
  • Across the five-year window, Depreciation & Amortization (CF) slumped 42.31% in 2023 and jumped 244.83% in 2024, its largest moves.
  • Envoy Medical's Depreciation & Amortization (CF) stood at $26000.0 in 2022, then plunged by 42.31% to $15000.0 in 2023, then soared by 220.0% to $48000.0 in 2024, then surged by 66.67% to $80000.0 in 2025, then dropped by 8.75% to $73000.0 in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $73000.0, $80000.0, and $76000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 381.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 120.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 749.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 40.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 67.10 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 78.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 123.40 Mn
10 Envoy Medical - - -274,000.00 73,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 73,000.00
Mar 31, 2026 73,000.00
Dec 31, 2025 80,000.00
Dec 31, 2025 80,000.00
Sep 30, 2025 76,000.00
Sep 30, 2025 76,000.00
Jun 30, 2025 100,000.00
Jun 30, 2025 100,000.00
Mar 31, 2025 61,000.00
Mar 31, 2025 61,000.00
Dec 31, 2024 48,000.00
Dec 31, 2024 48,000.00
Sep 30, 2024 49,000.00
Sep 30, 2024 49,000.00
Jun 30, 2024 100,000.00
Jun 30, 2024 100,000.00
Mar 31, 2024 34,000.00
Mar 31, 2024 34,000.00
Dec 31, 2023 15,000.00
Dec 31, 2023 15,000.00
Sep 30, 2023 29,000.00
Sep 30, 2023 29,000.00
Jun 30, 2023 29,000.00
Jun 30, 2023 29,000.00
Mar 31, 2023 27,000.00
Mar 31, 2023 27,000.00
Dec 31, 2022 26,000.00
Dec 31, 2022 26,000.00